Navigation Links
Study Explains How NSAIDs Halt Cancer Growth

Scientists have discovered that induction of a gene known as MDA-7/IL-24 is the molecular mechanism that enables nonsteroidal anti-inflammatory drugs (NSAIDs) to halt the// growth of cancer cells, a finding that could eventually lead to the development of targeted cancer treatments. Led by researchers at Beth Israel Deaconess Medical Center (BIDMC), in collaboration with scientists at Columbia University Medical Center, the new findings provide the answer to the long-puzzling question: How does this popular class of pain killers protect people from developing this deadly disease? The study appears in the Dec. 15 issue of the journal Cancer Research.

“Although observational studies had previously demonstrated that NSAIDs [such as aspirin, ibuprofen and sulindac] might be effective in the prevention and treatment of several common cancers, it wasn’t at all clear how this was happening,” explains the study’s senior author Towia Libermann, PhD, Director of the BIDMC Genomics Center and Associate Professor of Medicine at Harvard Medical School (HMS). “Now, after treating a number of different types of cancer cells in culture with a whole set of NSAIDs, we can point to this single gene which, when upregulated, kills cancer cells while sparing normal, healthy cells.” In recent years, a great deal of attention has focused on the link between inflammation and cancer. As the body’s immune response to tissue damage, acute inflammation serves as a natural defense to guard against injury or infection. However, in cases of chronic inflammation – for example, inflammatory bowel disease – certain signaling pathways that modulate the inflammatory processes become “stuck” in an activated state. Among other outcomes, this course of events leads to the release of molecules that enhance carcinogenesis and tumor progression at the site of the damage.

According to Libermann, it was these observations that originally prompted clinical and epidemiological researchers to begin examining whether routine use of anti-inflammatory agents had any effect on a person’s risk of developing several types of cancer, including colorectal cancer, breast cancer and ovarian cancer.

“Since then, studies have indeed shown that at clinically relevant concentrations, NSAIDs may be effective in the prevention and treatment of common cancers,” he says. These anti-cancer effects have been attributed, in large part, to NSAIDs’ potential to induce cell death, which appears to stem from the drugs’ inhibition of the COX (cyclooxygenase) enzymes, the primary mechanism by which NSAIDs guard against pain.

“However,” adds Libermann, “COX inhibition did not appear to be the only anti-cancer pathway being targeted by the compounds. We, therefore, undertook a comprehensive review of NSAIDs in order to decipher the precise molecular mechanisms that were at work.”

Using whole genome microarray analysis, Libermann and first author Luiz Zerbini, PhD, a researcher in the BIDMC Genomics Center and Instructor of Medicine at HMS, examined more than 20,000 genes to identify potential mechanisms for cell death induction.

“When we analyzed the genes that were upregulated by NSAIDS, one in particular stood out from the rest,” says Zerbini. “And that was MDA-7/IL-24.”

A cancer specific cytokine, MDA-7/IL-24 was already familiar to the investigators as a novel tumor suppressor gene, says Libermann. “Viral delivery of MDA-7/IL-24 is currently being evaluated in several clinical trials as a therapeutic agent against various cancers, and enhanced levels of the gene have also been correlated with prolonged survival in patients with non-small lung cancer.” Following their identification of this cytokine, the investigators used an interfering RNA approach to block MDA-7/IL-24 gene expression in cancer cells, thereby demonstrating the necessity of NSAID-mediated induction of the gene to destroy cancer cells. They also used a mouse m odel of prostate cancer to demonstrate that when MDA-7/IL-24 was blocked, the anti-cancer effects of the NSAIDs were diminished.

Finally, building on their earlier work demonstrating the relevance of GADD45 (Growth Arrest DNA Damage) family members to cancer cell death (as well as previous work by study coauthor Paul Fisher, MPh, PhD, of Columbia University Medical Center) Libermann and Zerbini identified GADD45 alpha and gamma as the critical mediators of this course of events, showing that the ability of NSAIDs to induce apoptosis was dependent on their abilities to induce MDA-7/IL-24 expression, leading to enhanced GADD45 alpha and gamma expression.

“Current clinical trials are evaluating a range of NSAIDs for a variety of cancers without any clear vision of the best way to use them,” notes Libermann. “The fact that upregulation of this single gene – MDA-7/IL-24 -- correlated not only with cell death induction of numerous types of cancer but also among various diverse classes of NSAIDs, makes this discovery particularly exciting. The level of MDA-7/IL-24 gene expression in cancer patients may emerge as a new biomarker for monitoring patients’ responses to certain therapies, and may help determine whether drugs such as NSAIDs are hitting their intended targets.”

In addition to Libermann, Zerbini and Fisher, study coauthors include BIDMC investigators Akos Czibere, MD, Yihong Wang, MD, Hasan Otu, PhD, Marie Joseph, Yuko Takayasu, MD, Moriah Silver, Xuesong Gu, PhD, Kriangsak Ruchusatsawat, PhD, Linglin Li, MSc, and Jin-Rong Zhou, PhD; Ricardo Correa, PhD, of The Salk Institute for Biological Studies in La Jolla, California; and Devanand Sarkar, PhD, of the Columbia University Medical Center, College of Physicians and Surgeons, New York. This study was funded, in part, by grants from the National Institutes of Health, the U.S. Department of Defense, the Hershey Foundation, the Samuel Waxman Cancer Research Foundation and the Chernow En dowment.

Source-Newswise
SRM
'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: